US › Healthcare

Prothena Corporation plc (PRTA)

US · Healthcare · Biotechnology

$8.49+1.92%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$51.1M
Revenue YoY
+1706.4%
Net profit
$32.7M
Profit YoY
+154.4%
EPS
$0.68
EPS estimate
$-0.30
Net margin
64.1%

EPS came in at 0.68 against a street estimate of -0.30 — a beat of 326.7%.

Key statistics

Market cap
$436.1M
Forward P/E
10.6
P/B
1.36
Book value
$5.89
EPS (TTM)
$-2.81
52-week high
$11.80
52-week low
$7.28
50-day MA
$9.05
200-day MA
$9.64
Beta
-0.35

Analyst view

Analysts rate Prothena Corporation plc a buy (3 buy, 2 hold, 1 sell out of 6) with an average price target of $21.40.

Shareholding

Insiders
20.18%
Institutions
90.76%

Largest institutional holders

FundStake
FMR Inc14.42%
Rubric Capital Management LP9.55%
BlackRock Inc8.87%
Vanguard Group Inc4.09%
State Street Corp3.70%
D. E. Shaw & Co LP3.37%
ADAR1 Capital Management LLC3.02%
Acadian Asset Management LLC2.96%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Prothena Corporation plc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.